DK0901633T3 - Screening af midler til behandling af Alzheimers sygdom - Google Patents

Screening af midler til behandling af Alzheimers sygdom

Info

Publication number
DK0901633T3
DK0901633T3 DK97923188T DK97923188T DK0901633T3 DK 0901633 T3 DK0901633 T3 DK 0901633T3 DK 97923188 T DK97923188 T DK 97923188T DK 97923188 T DK97923188 T DK 97923188T DK 0901633 T3 DK0901633 T3 DK 0901633T3
Authority
DK
Denmark
Prior art keywords
agent
alzheimer
disease
filaments
treatment
Prior art date
Application number
DK97923188T
Other languages
English (en)
Inventor
Michel Goedert
Ross Jakes
Maria Grazia Spillantini
Masato Hasegawa
Michael John Smith
Richard Anthony Crowther
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council filed Critical Medical Res Council
Application granted granted Critical
Publication of DK0901633T3 publication Critical patent/DK0901633T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
    • Y10T436/144444—Glucose

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
DK97923188T 1996-05-23 1997-05-20 Screening af midler til behandling af Alzheimers sygdom DK0901633T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9610829.5A GB9610829D0 (en) 1996-05-23 1996-05-23 Screening of agents for treatment of azlheimers disease
PCT/GB1997/001356 WO1997044669A1 (en) 1996-05-23 1997-05-20 Screening of agents for treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
DK0901633T3 true DK0901633T3 (da) 2003-06-16

Family

ID=10794213

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97923188T DK0901633T3 (da) 1996-05-23 1997-05-20 Screening af midler til behandling af Alzheimers sygdom

Country Status (10)

Country Link
US (1) US6245575B1 (da)
EP (1) EP0901633B1 (da)
JP (1) JP2001503509A (da)
AT (1) ATE235058T1 (da)
DE (1) DE69719978T2 (da)
DK (1) DK0901633T3 (da)
ES (1) ES2194198T3 (da)
GB (1) GB9610829D0 (da)
PT (1) PT901633E (da)
WO (1) WO1997044669A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025640A2 (en) * 1996-12-13 1998-06-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel methods for testing inhibitors of paired helical filaments and uses for treatment of alzheimer's disease
CA2504035A1 (en) * 2002-11-01 2004-05-21 Proteotech, Inc. Amyloid plaque formation by glycosaminoglycans
FR2888937B1 (fr) * 2005-07-21 2012-10-26 Biomerieux Sa Procede de detection des fcpa utilisant un agent d'agregation des fcpa et un agent de capture des agregats formes
KR101095630B1 (ko) * 2009-06-17 2011-12-19 주식회사 이노파마스크린 베타 아밀로이드 펩타이드와 vegf의 상호작용을 억제하는 물질을 탐색 방법 및 그에 의해서 탐색된 저해제
JP2013032295A (ja) * 2009-12-04 2013-02-14 Kaneka Corp タウ蛋白の吸着材および吸着除去システム
EP3602046A1 (en) * 2017-03-28 2020-02-05 Janssen Vaccines & Prevention B.V. Methods for detection of tau protein aggregation modulating compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164295A (en) * 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
DE69227380T3 (de) 1991-11-12 2007-01-11 Prana Biotechnology Ltd., South Melbourne Verfahren zur bestimmung und behandlung von alzheimer-krankheit
WO1993011231A1 (en) 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis

Also Published As

Publication number Publication date
WO1997044669A1 (en) 1997-11-27
EP0901633A1 (en) 1999-03-17
JP2001503509A (ja) 2001-03-13
ES2194198T3 (es) 2003-11-16
ATE235058T1 (de) 2003-04-15
EP0901633B1 (en) 2003-03-19
GB9610829D0 (en) 1996-07-31
DE69719978T2 (de) 2003-12-18
US6245575B1 (en) 2001-06-12
PT901633E (pt) 2003-07-31
DE69719978D1 (de) 2003-04-24

Similar Documents

Publication Publication Date Title
EE200100645A (et) Amüloidogeense haiguse preventsioon ja ravi
EA200602015A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
CY1105922T1 (el) Χρηση υποκατεστημενων παραγωγων αζετιδινονης στη θepαπεια ασθενειας alzheimer
NO962130L (no) Synergistisk behandling av Parkinsons sykdom
ATE214924T1 (de) Verwendung von nebivolol als anti-atherogenisches mittel
BR9909382A (pt) Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
MXPA05003621A (es) Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
DE69429527D1 (de) Inhibitoren von beta-amyloid-protein-herstellung
DK1160256T4 (da) Monoklonalt antistof der er specifikt for beta-A4 (1-42)-peptid
DE59611341D1 (de) Verwendung von saccharid-konjugaten
ATE330631T1 (de) Antikörperfragmente zur lokalen behandlung von augenerkrankungen
ES2136654T3 (es) Herramientas para el diagnostico y tratamiento de la enfermedad de alzheimer.
EA200401070A1 (ru) Способы лечения сосудистых заболеваний
NO20011891L (no) Anvendelse av radioligander for screening av inhibitorer av amyloid-<beta>-peptid produksjon
DE69735545D1 (de) Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktors
RU93004982A (ru) Способ лечения эндотоксинового шока с применением антиадгезивных антител
DE69129460D1 (de) Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
DK0871457T3 (da) Isolerede stromaceller og fremgangsmåder til anvendelse heraf
MXPA03000316A (es) Reactivos y metodos para la identificacion de agentes de enlace.
PT901633E (pt) Rastreio de agentes para tratamento da doenca de alzheimer
DE69425820D1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
EP1039931A4 (en) MULTIVALENT RECOMBINANT ANTIBODIES FOR THE TREATMENT OF HUMAN RHINOVIRUS (HRV) INFECTIONS
ATE305052T1 (de) Drogen untersuchungssystem
NO20012849L (no) Ny terapeutisk anvendelse for hepariner med lav molekylvekt